Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adherex Technologies Inc. (FENC : NSDQ)

• Company Description    Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $8.76 Daily Weekly Monthly 20 Day Moving Average: 56,200 shares Shares Outstanding: 27.91 (millions) Market Capitalization: $244.50 (millions) Beta: 0.58 52 Week High: $9.42 52 Week Low: $3.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.70% 0.89% 12 Week 11.45% 1.24% Year To Date 38.61% 27.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL PO BOX 13628 68 TW ALEXANDER DRIVE - RESEARCH TRIANGLE PARK,NC 27709 USA ph: 919-636-4530 fax: 919-890-0490 None http://www.fennecpharma.com

• General Corporate Information    Officers Jeffrey Hackman - Chief Executive Officer Robert Andrade - Chief Financial Officer Khalid Islam - Director Chris A. Rallis - Director Marco Brughera - Director Peer Information Adherex Technologies Inc. (CORR.) Adherex Technologies Inc. (RSPI) Adherex Technologies Inc. (CGXP) Adherex Technologies Inc. (BGEN) Adherex Technologies Inc. (GTBP) Adherex Technologies Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31447P100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 27.91 Most Recent Split Date: 9.00 (0.33:1) Beta: 0.58 Market Capitalization: $244.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: 105.12 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 271.24 Price / Sales: 7.34 EPS Growth vs. Year Ago Period: 45.00% vs. Previous Quarter: -175.00% Sales Growth vs. Year Ago Period: 32.91% vs. Previous Quarter: 10.30% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -23.92 03/31/25 - -26.37 12/31/24 - -0.12 Current Ratio 06/30/25 - 4.85 03/31/25 - 5.13 12/31/24 - 6.38 Quick Ratio 06/30/25 - 4.59 03/31/25 - 4.97 12/31/24 - 6.22 Operating Margin 06/30/25 - -35.05 03/31/25 - -45.52 12/31/24 - -0.15 Net Margin 06/30/25 - -35.05 03/31/25 - -45.52 12/31/24 - -0.15 Pre-Tax Margin 06/30/25 - -35.05 03/31/25 - -45.53 12/31/24 - -0.15 Book Value 06/30/25 - -0.27 03/31/25 - -0.21 12/31/24 - -0.21 Inventory Turnover 06/30/25 - 2.33 03/31/25 - 2.10 12/31/24 - 1.99 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©